| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328331 | Acta Haematologica Polonica | 2014 | 4 Pages |
Abstract
Multiple myeloma (MM) is a malignant and still incurable proliferative disease of the hematopoietic system. Introduction to therapy over a decade ago new therapeutic strategies, including immunomodulatory drugs (IMiDs) significantly improved the prognosis in this type of cancer. Despite high response rate multiple myeloma is characterized by a relapsing course in most patients and becomes more resistance to treatment. The article presents the case of a 49-year-old patient with relapsed multiple myeloma treated with lenalidomide monotherapy for 36 months.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ewa Stefanko, Tomasz Wróbel,